Patents by Inventor Edward F. Schnipper
Edward F. Schnipper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230218874Abstract: Described herein is a drug product delivery device and method of delivering a drug on a swab. The drug product delivery device may include an applicator platform housed within a rigid housing. The applicator platform may be in the form of a plunger. One or more fluidic channels carry fluid from a storage chamber to an applicator. A frangible seal is attached to the plunger between the storage chamber and the applicator. The frangible seal blocks the fluid from moving from the storage chamber into one or more fluidic channels. Actuation of the plunger causes the frangible seal to be ruptured, which causes the fluid to exit the fluid storage chamber and enter into the one or more fluidic channels. The one or more fluidic channels carry the fluid to the applicator.Type: ApplicationFiled: February 27, 2023Publication date: July 13, 2023Applicant: Anergent Pharmaceuticals, Inc.Inventors: Thomas H. Cauley, Edward F. Schnipper, Bruce A. Cohen, Nooshin Azimi
-
Patent number: 11623075Abstract: Described herein is a drug product delivery device and method of delivering a drug on a swab. The drug product delivery device may include an applicator platform housed within a rigid housing. The applicator platform may be in the form of a plunger. The foil drug reservoir cap creates a fluid storage chamber disposed between the foil drug reservoir cap and the plunger. A series of fluidic channels carry fluid from the fluid storage chamber to an applicator. A frangible seal is attached to the plunger between the fluid storage chamber and the applicator. The frangible seal blocks a fluid from moving from the fluid storage chamber into the series of fluidic channels. Actuation of the plunger causes the frangible seal to be ruptured, which causes the fluid to exit the fluid storage chamber and enter into the fluidic channels. The fluidic channels carry the fluid to the applicator.Type: GrantFiled: May 28, 2020Date of Patent: April 11, 2023Assignee: ANERGENT PHARMACEUTICALS, INC.Inventors: Thomas H. Cauley, Edward F. Schnipper, Bruce A. Cohen, Nooshin Azimi
-
Patent number: 11026920Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.Type: GrantFiled: March 2, 2020Date of Patent: June 8, 2021Assignee: VYNE THERAPEUTICS INC.Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
-
Publication number: 20200376241Abstract: Described herein is a drug product delivery device and method of delivering a drug on a swab. The drug product delivery device may include an applicator platform housed within a rigid housing. The applicator platform may be in the form of a plunger. The foil drug reservoir cap creates a fluid storage chamber disposed between the foil drug reservoir cap and the plunger. A series of fluidic channels carry fluid from the fluid storage chamber to an applicator. A frangible seal is attached to the plunger between the fluid storage chamber and the applicator. The frangible seal blocks a fluid from moving from the fluid storage chamber into the series of fluidic channels. Actuation of the plunger causes the frangible seal to be ruptured, which causes the fluid to exit the fluid storage chamber and enter into the fluidic channels. The fluidic channels carry the fluid to the applicator.Type: ApplicationFiled: May 28, 2020Publication date: December 3, 2020Applicant: Statim Pharmaceuticals, Inc.Inventors: Thomas H. Cauley, Edward F. Schnipper, Bruce A. Cohen, Nooshin Azimi
-
Publication number: 20200306224Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.Type: ApplicationFiled: March 2, 2020Publication date: October 1, 2020Inventors: Xiaoming ZHANG, Edward F. SCHNIPPER, Andrew J. PERLMAN, James W. LARRICK
-
Patent number: 10702499Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.Type: GrantFiled: March 25, 2019Date of Patent: July 7, 2020Assignee: MENLO THERAPEUTICS INC.Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
-
Patent number: 10617671Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.Type: GrantFiled: March 25, 2019Date of Patent: April 14, 2020Assignee: MENLO THERAPEUTICS INC.Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
-
Publication number: 20200054604Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.Type: ApplicationFiled: March 25, 2019Publication date: February 20, 2020Inventors: Xiaoming ZHANG, Edward F. SCHNIPPER, Andrew J. PERLMAN, James W. LARRICK
-
Publication number: 20200054603Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.Type: ApplicationFiled: March 25, 2019Publication date: February 20, 2020Inventors: Xiaoming ZHANG, Edward F. SCHNIPPER, Andrew J. PERLMAN, James W. LARRICK
-
Patent number: 10278952Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.Type: GrantFiled: April 10, 2018Date of Patent: May 7, 2019Assignee: Menlo Therapeutics Inc.Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
-
Patent number: 10278953Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.Type: GrantFiled: April 18, 2018Date of Patent: May 7, 2019Assignee: Menlo Therapeutics Inc.Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
-
Publication number: 20190070396Abstract: Medical devices and methods for rapid and efficient systemic drug delivery via mucous membranes, particularly oral mucosae, are described. Use of such devices and methods are particularly easy for people without any medical training to employ should they be called upon to provide emergency medical treatment for a victim suffering from anaphylactic shock, opioid overdose, or other life-threatening events. In some embodiments, the device includes an applicator tip with a porous application layer positioned on the end of an elongate handle. The device may also include various means for disrupting a barrier to facilitate mixing of compounds, including an active ingredient, and permit flow of the compounds from a reservoir to the applicator tip.Type: ApplicationFiled: November 6, 2018Publication date: March 7, 2019Applicant: Statim Pharmaceuticals, Inc.Inventors: Randolph M. Johnson, Nooshin T. Azimi, Edward F. Schnipper, Thomas H. Cauley, III
-
Publication number: 20180325866Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.Type: ApplicationFiled: April 10, 2018Publication date: November 15, 2018Inventors: Xiaoming ZHANG, Edward F. SCHNIPPER, Andrew J. PERLMAN, James W. LARRICK
-
Publication number: 20180325867Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.Type: ApplicationFiled: April 18, 2018Publication date: November 15, 2018Inventors: Xiaoming ZHANG, Edward F. SCHNIPPER, Andrew J. PERLMAN, James W. LARRICK
-
Patent number: 9974769Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.Type: GrantFiled: June 16, 2017Date of Patent: May 22, 2018Assignee: MENLO THERAPEUTICS INC.Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
-
Patent number: 9968588Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.Type: GrantFiled: June 16, 2017Date of Patent: May 15, 2018Assignee: MENLO THERAPEUTICS INC.Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
-
Publication number: 20170348283Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.Type: ApplicationFiled: June 16, 2017Publication date: December 7, 2017Inventors: Xiaoming ZHANG, Edward F. SCHNIPPER, Andrew J. PERLMAN, James W. LARRICK
-
Publication number: 20170348282Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.Type: ApplicationFiled: June 16, 2017Publication date: December 7, 2017Inventors: Xiaoming ZHANG, Edward F. SCHNIPPER, Andrew J. PERLMAN, James W. LARRICK
-
Patent number: 9737508Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.Type: GrantFiled: September 20, 2016Date of Patent: August 22, 2017Assignee: MENLO THERAPEUTICS INC.Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
-
Patent number: 9737507Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.Type: GrantFiled: September 19, 2016Date of Patent: August 22, 2017Assignee: MENLO THERAPEUTICS INC.Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick